About

The Australian Therapeutic Goods Administration (TGA) made international headlines in February 2023 when it rescheduled psilocybin and MDMA from Schedule 9 (prohibited) to Schedule 8 (controlled) for specific therapeutic applications. This was the first national regulatory approval of psychedelic medicines anywhere in the world.

Under the TGA's framework: - Authorized psychiatrists can prescribe psilocybin for treatment-resistant depression - Authorized psychiatrists can prescribe MDMA for PTSD - Prescribing requires application to the Special Access Scheme - Sessions must occur in clinical settings with trained supervision

As of 2026, a small number of Australian psychiatrists have obtained authorization and begun treating patients — making Australia the first country with a legal, regulated pathway for clinical psychedelic therapy. The program is expensive (out of pocket, AUD $25,000+) and limited in scale, but it is operational.

This development has significant implications for US and international regulatory discussions, as it demonstrates that national approval and clinical integration is practically achievable.

Why It Matters

Australia's TGA approval is the proof of concept that national regulatory approval of psychedelic medicine is achievable. It directly informs FDA discussions, provides real-world safety data from an approved prescribing context, and has created the first legal clinical psychedelic therapy program at the national level.

Related